These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1052 related items for PubMed ID: 11085347

  • 1. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB, Valero V, Hortobagyi G.
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.
    Pronk LC, Stoter G, Verweij J.
    Cancer Treat Rev; 1995 Sep; 21(5):463-78. PubMed ID: 8556719
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
    Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J.
    Health Technol Assess; 2000 Sep; 4(17):1-113. PubMed ID: 11074389
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Scheduling of taxanes: a review.
    Woodward EJ, Twelves C.
    Curr Clin Pharmacol; 2010 Aug; 5(3):226-31. PubMed ID: 20406166
    [Abstract] [Full Text] [Related]

  • 17. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A, Guarneri V, Landucci E, Orlandini C, Rondini M, Salvadori B, Ricci S, Conte PF.
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [Abstract] [Full Text] [Related]

  • 18. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
    Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A, Roche H.
    Ann Oncol; 1996 Feb; 7(2):165-71. PubMed ID: 8777173
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.